May 31, 2023
Stories this photo appears in:
Diabetics, Obese Gain Way to Pay for Egregiously Expensive GLP-1 Weight Loss Medications
With the National Institutes of Health, Mayo Clinic and other esteemed medical research institutions validating the significant efficacy of GLP-1 medications for inducing weight loss among type 2 diabetics and clinically obese persons who are appropriately prescribed such medications by their doctor, the high costs of GLP-1 treatment options—coupled with severely limited or non-coverage by insurance providers—is tempering the excitement that surrounds this wellness advancement.